Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului.
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
D01BA02 TERBINAFINUM COMPR. 250 mg
LAMISIL(R) 250 mg NOVARTIS PHARMA GMBH
TERBINARAN 250 mg RANBAXY UK LIMITED
TERBISIL(R) 250 mg 250 mg GEDEON RICHTER LTD.
______________________________________________________________________________
| 227 |D05AX02| CALCIPOTRIOLUM* | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
D05AX02 CALCIPOTRIOLUM CREMA 50 µg/g
DAIVONEX 50 µg/g LEO PHARMACEUTICAL
PRODUCTS
D05AX02 CALCIPOTRIOLUM UNGUENT 50 µg/g
DAIVONEX UNGUENT 50 µg/g LEO PHARMACEUTICAL
PRODUCTS
D05AX02 CALCIPOTRIOLUM SOL. CUT. 50 µg/ml
DAIVONEX SOLUŢIE CUTANATĂ 50 µg/ml LEO PHARMACEUTICAL
PENTRU SCALP PRODUCTS
D05AX02 CALCIPOTRIOLUM UNGUENT 0.005%
SOREL(R) unguent 0,005% 0.005% LEK PHARMACEUTICALS D.D.
______________________________________________________________________________
| 228 |D05AX52| COMBINATII (CALCIPOTRIOLUM + | |
| | | BETAMETHASONUM)* | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
D05AX52 COMBINATII UNGUENT
(CALCIPOTRIOLUM +
BETAMETHASONUM)
DAIVOBET(R) UNGUENT LEO PHARMACEUTICAL
PRODUCTS
______________________________________________________________________________
| 230 |D06AX01| ACIDUM FUSIDICUM | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
D06AX01 ACIDUM FUSIDICUM CREMA 2,00%
FUCIDIN(R) 2% LEO PHARMACEUTICAL
PRODUCTS
D06AX01 ACIDUM FUSIDICUM UNGUENT 2,00%
FUCIDIN(R) 2% LEO PHARMACEUTICAL
PRODUCTS
______________________________________________________________________________
| 231 |D06AXN1| COMBINATII (NEOMYCINUM + BACITRACINUM) | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
D06AXN1 COMBINATII PULB. CUT.
(NEOMYCINUM +
BACITRACINUM)
BANEOCIN(R) SANDOZ GMBH
D06AXN1 COMBINATII UNGUENT
(NEOMYCINUM +
BACITRACINUM)
BANEOCIN(R) SANDOZ GMBH
NEOBACIN DAR AL DAWA PHARMA SRL
______________________________________________________________________________
| 232 |D06BA01| SULFADIAZINUM | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
D06BA01 SULFADIAZINUM CREMA 1,00%
DERMAZIN(R) 1% 1% LEK PHARMACEUTICALS D.D.
______________________________________________________________________________
| 233 |D06BB04| PODOPHYLLOTOXINUM* | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
D06BB04 PODOPHYLLOTOXINUM CREMA 1,5 mg/g
WARTEC 1,5 mg/g 1,5 mg/g STIEFEL LABORATORIES (UK)
LTD.
D06BB04 PODOPHYLLOTOXINUM SOL. CUT. 5 mg/ml
CONDYLINE 5 mg/ml ASTELLAS PHARMA EUROPE
B.V.
Prescriere limitată: Pentru tratamentul verucilor.
______________________________________________________________________________
| 235 |D07AB02| HYDROCORTISONUM BUTYRATUM | Protocol: D001L |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
D07AB02 HYDROCORTISONUM CREMA 0.1%
BUTYRATUM
LOCOID(R) cremă 0,1% 0.1% ASTELLAS PHARMA EUROPE BV
LOCOID(R)LIPOCREAM 0,1% 0.1% ASTELLAS PHARMA EUROPE
B.V.
D07AB02 HYDROCORTISONUM EMULSIE CUT. 0.1%
BUTYRATUM
LOCOID CRELO(R) 0,1% 0.1% ASTELLAS PHARMA EUROPE BV
D07AB02 HYDROCORTISONUM SOL. CUT. 0.1%
BUTYRATUM
LOCOID(R) 0.1% ASTELLAS PHARMA EUROPE
B.V.
______________________________________________________________________________
| 236 |D07AC13| MOMETASONUM | Protocol: D001L |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
D07AC13 MOMETASONUM CREMA 1 mg/g
ELOCOM 1 mg/g SCHERING PLOUGH EUROPE
D07AC13 MOMETASONUM SOL. CUT. 1 mg/g
ELOCOM 1 mg/g SCHERING PLOUGH EUROPE
D07AC13 MOMETASONUM UNGUENT 1 mg/g
ELOCOM 1 mg/g SCHERING PLOUGH EUROPE
______________________________________________________________________________
| 237 |D07AC14| METHYLPREDNISOLONUM ACEPONAT | Protocol: D001L |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
D07AC14 METHYLPREDNISOLONUM EMULSIE CUT. 0.1%
ACEPONAT
ADVANTAN(R) MILK 0.1% INTENDIS GMBH
D07AC14 METHYLPREDNISOLONUM CREMA 1 mg/g
ACEPONAT
ADVANTAN 1 mg/g INTENDIS GmbH
D07AC14 METHYLPREDNISOLONUM UNGUENT 1 mg/g
ACEPONAT
ADVANTAN 1 mg/g INTENDIS GmbH
______________________________________________________________________________
| 238 |D07AC17| FLUTICASONUM | Protocol: D001L |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
D07AC17 FLUTICASONUM CREMA 0.05%
CUTIVATE 0.05% GLAXO WELLCOME UK LIMITED
D07AC17 FLUTICASONUM UNGUENT 0.005%
CUTIVATE 0.005% GLAXO WELLCOME UK LIMITED
______________________________________________________________________________
| 239 |D07AD01| CLOBETASOLUM* | Protocol: D001L |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
D07AD01 CLOBETASOLUM CREMA 0.05%
DERMOVATE 0.05% GLAXOWELLCOME UK LTD.
D07AD01 CLOBETASOLUM SOL. CUT. 0.05%
DERMOVATE(R) 0.05% GLAXO WELLCOME UK LTD.
D07AD01 CLOBETASOLUM UNGUENT 0.05%
DERMIONE 0.05% OZONE LABORATORIES LTD.
DERMOVATE 0.05% GLAXOWELLCOME UK LTD.
______________________________________________________________________________
| 240 |D07CA01| COMBINATII (HYDROCORTISONUM + | Protocol: D001L |
| | | ANTIINFECTIOASE) | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
D07CA01 COMBINATII CREMA
(HYDROCORTISONUM +
ANTIINFECTIOASE)
FUCIDIN(R) H LEO PHARMACEUTICAL
PRODUCTS
PIMAFUCORT ASTELLAS PHARMA EUROPE
B.V.
D07CA01 COMBINATII UNGUENT
(HYDROCORTISONUM +
ANTIINFECTIOASE)
PIMAFUCORT ASTELLAS PHARMA EUROPE
B.V.
______________________________________________________________________________
| 241 |D07CC01| COMBINATII (BETAMETHASONUM + | Protocol: D001L |
| | | ANTIINFECTIOASE) | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
D07CC01 COMBINATII CREMA
(BETAMETHASONUM +
ANTIINFECTIOASE)
FUCICORT(R) LEO PHARMACEUTICAL
PRODUCTS
______________________________________________________________________________
| 242 |D07XC03| COMBINATII (MOMETASONUM + | Protocol: D001L |
| | | AC. SALICILICUM) | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
D07XC03 COMBINATII UNGUENT
(MOMETASONUM + AC.
SALICILICUM)
ELOSALIC SCHERING PLOUGH EUROPE
______________________________________________________________________________
| 243 |D10AD54| COMBINATII (MOMETASONUM + ERITROMICINUM) | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
D10AD54 COMBINATII GEL 0,05%/0,2%
(ISOTRETINOINUM +
ERITROMICINUM)
ISOTREXIN GEL 0,05%/0,2% STIEFEL LABORATORIES (UK)
LTD.
______________________________________________________________________________
| 244 |D10AX03| ACIDUM AZELAICUM | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
D10AX03 ACIDUM AZELAICUM CREMA 200 mg/g
SKINOREN 200 mg/g INTENDIS GmbH
D10AX03 ACIDUM AZELAICUM GEL 15%
SKINOREN(R) 15% 15% INTENDIS GMBH
______________________________________________________________________________
| 245 |D10BA01| ISOTRETINOINUM** | |
|_______|_______|____________________________________________|_________________|
Dostları ilə paylaş: |